Akut– Kronik böbrek hastalığı

Diyabetik böbrek hastalığı

Hipertansiyon

Glomerülonefritler

Diyaliz, prediyaliz hasta takibi

Sıvı elektrolit bozuklukları

Böbrek nakilli hasta takibi

İdrar yolu enfeksiyonu

Polikistik böbrek hastalığı

Ödem

1. Thyroid function and cardiovascular events in chronic kidney disease patients. Afsar B, Yilmaz MI, Siriopol D, Unal HU, Saglam M, Karaman M, Gezer M, Sonmez A, Eyileten T, Aydin I, Hamcan S, Oguz Y, Covic A, Kanbay M.  J Nephrol. 2017 Apr;30(2):235-242. doi: 10.1007/s40620-016-0300-y. Epub 2016 Apr 2 
2. The relationship between IL-10 levels and cardiovascular events in patients with CKD .Yilmaz MI, Solak Y, Saglam M, Cayci T, Acikel C, Unal HU, Eyileten T, Oguz Y, Sari S, Carrero JJ, Stenvinkel P, Covic A, Kanbay M. Clin J Am Soc Nephrol. 2014 Jul;9(7):1207-16. doi: 10.2215/CJN.08660813
3. Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events .Yilmaz MI, Siriopol D, Saglam M, Unal HU, Karaman M, Gezer M, Kilinc A, Eyileten T, Guler AK, Aydin İ, Vural A, Oguz Y, Covic A, Ortiz A, Kanbay M. Calcif Tissue Int. 2016 Aug;99(2):121-30. doi: 10.1007/s00223-016-0136-4
4. Ultrasonographic evaluation of the femoral cartilage thickness in patients with chronic renal failure .Ünal HU, Tok F, Adıgüzel E, Gezer M, Aydın İ, Yılmaz B, Oğuz Y..  Ren Fail. 2016;38(4):600-4
5. Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival . Kanbay M, Afsar B, Siriopol D, Unal HU, Karaman M, Saglam M, Gezer M, Taş A, Eyileten T, Guler AK, Aydin İ, Oguz Y, Tarim K, Covic A, Yilmaz MI. Eur J Intern Med. 2016 Sep;33:81-7
6. The Relationship Between Plasma Whole Blood Viscosity and Cardiovascular Events in Patients With Chronic Kidney Disease. Celik T, Yilmaz MI, Balta S, Ozturk C, Unal HU, Aparci M, Karaman M, Demir M, Yildirim AO, Saglam M, Kilic S, Eyileten T, Aydin İ, Iyisoy A. .Clin Appl Thromb Hemost. 2017 Sep;23(6):663-670
7. Contrast-induced acute kidney injury/ contrast-induced nephropathy may be related to additional risk factors. Ünal HU, Başaran Y, Akoğlu H. Anatol J Cardiol. 2018 Feb;19(2):155
8. IL-33 and ST2 levels in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events, and survival. Gungor O, Unal HU, Guclu A, Gezer M, Eyileten T, Guzel FB, Altunoren O, Erken E, Oguz Y, Kocyigit I, Yilmaz MI.. PLoS One. 2017 Jun 14;12(6)
9. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Kanbay M, Yilmaz MI, Sonmez A, Solak Y, Saglam M, Cakir E, Unal HU, Arslan E, Verim S, Madero M, Caglar K, Oguz Y, McFann K, Johnson RJ. Am J Nephrol. 2012;36(4):324-31 
10. The Triglyceride to High-Density Lipoprotein Cholesterol Ratio Is a Useful Marker to Predict Unfavorable Cardiovascular Outcomes, But Other Confounding Factors Should Be Considered . Ünal HU, Başaran Y, Gezer M..J Clin Hypertens (Greenwich). 2016 Sep;18(9):951 
11. Serum calcitonin and endothelial dysfunction in chronic kidney disease: a novel risk factor? Kanbay M, Yilmaz MI, Afsar B, Saglam M, Akgul EO, Cayci T, Caglar K, Unal HU, Gok M, Vural A, Covic A. Int Urol Nephrol. 2013 Feb;45(1):151-6 
12. Mitral annular calcification and the serum osteocalcin level in patients with chronic kidney disease. Ünal HU, Çelik M, Gökoğlan Y, Çetinkaya H, Gök M, Karaman M, Yilmaz MI, Eyileten T, Oğuz Y. Ren Fail . 2014 Nov;36(10):1481-5 
13. Endogenous testosterone ,endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Steinvinkel P, Yaman H, Eyileten T,Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU; Yenicesu M, Carrero JJ. Clin J Am Soc Nephrol. 2011 Jul 6(7):1617-25. Epub 2011 Jun 23 
14. Endogenous testosterone ,endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Steinvinkel P, Yaman H, Eyileten T,Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU; Yenicesu M, Carrero JJ. Clin J Am Soc Nephrol. 2011 Jul 6(7):1617-25. Epub 2011 Jun 23 
15. The ımportance of ımmunofluorescence staining in patients with primary fsgs. Ünal HU, Çakar M, Yavan İ, Özcan  A, Yılmaz MI, Çetinkaya H, Gök M, Eyileten T, Vural A, Oğuz Y. Turkish J Nephrol 2014; 23: 51-55 tndt.2014.1001.10